Mersana Therapeutics

MRSN

Market cap $53.4M

The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice President of Investor Relations & Corporate Communications Martin H.

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $4.08 per share versus the Zacks Consensus Estimate of a loss of $3.75. This compares to a loss of $5 per share a year ago.

CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025.

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company's common stock (the Reverse Stock Split), effective at 5:00 p.m. Eastern Time on July 25, 2025.

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.

CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications Marty Huber - President & Chief Executive Officer Brian DeSchuytner - Chief Operating Officer & Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Charles Zhu - LifeSci Capital Michael Schmidt - Guggenheim Jonathan Chang - Leerink Partners Colleen Kusy - Baird Andy Hsieh - William Blair Karina Rabayeva - Truist Jeet Mukherjee - BTIG Operator Good morning, and welcome to Mersana Therapeutics First Quarter 2025 Conference Call. Currently all participants are in a listen-only mode.